Key U.S. senator remains concerned over ChemChina-Syngenta deal
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
A Syngenta logo is pictured in their office in Singapore, February 12, 2016. REUTERS/Edgar Su/File Photo
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
BEIJING (Reuters) - A powerful U.S. senator said he is concerned that state-owned ChemChina, which is buying Swiss crop protection and seed group Syngenta
Some Chinese state-owned entities have argued that they have sovereign immunity and thus can't be sued in U.S. courts under the U.S. Foreign Sovereign Immunities Act (FSIA) of 1976.
The acquisition by China National Chemical Corp (ChemChina) [CNNCC.UL] of Syngenta, the largest global investment by a Chinese company, won U.S. regulatory clearance in August despite concerns from some lawmakers over U.S. food security.
This week, a U.S. congressional panel urged lawmakers to take action to ban Chinese state-owned firms from acquiring U.S. companies.
In a Nov. 9 letter to U.S. Senator Chuck Grassley that was posted on his website, ChemChina said its U.S.-incorporated businesses are subject to U.S. civil law, and that FSIA does not apply to commercial activity.
Grassley, who represents the U.S. agricultural powerhouse state of Iowa, said in a Nov. 16 response that he remained concerned that ChemChina could seek to shield itself from U.S. court jurisdiction.
"While ChemChina indicated that immunity would not extend to Syngenta's U.S. business, the company failed to note that immunity would otherwise apply to a wholly state-owned entity," he said on his website.
Some legal experts say the sovereign immunity defense, intended under international law to shield governments from legal rulings made by a foreign power, typically does not apply to commercial cases.
ChemChina's acquisition is now in the process of gaining approval from the European Commission, and the deal is expected to be closed around the end of March.
In its letter to Grassley, ChemChina said the Chinese government does not interfere with ChemChina's operations and has not directed ChemChina or any of its affiliates to engage in price-fixing with competitors.
"Syngenta will continue to have its same strategy, management, people and culture and its headquarters in Basel. No jobs will be lost and no jobs will go overseas as a result of this transaction," it said.
ChemChina also said the Chinese government does not interfere with its operations and has not directed ChemChina or any of its affiliates to engage in price fixing with competitors.
(Reporting by Chen Aizhu; Edited by Tony Munroe and Tom Hogue)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
- Former President George H.W. Bush may be moved soon from intensive care
- First days of Trump era signal America's deepening political divide
Create E-mail Alert Related CategoriesReuters
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!